Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
Ruxolitinib (INCB018424)
Cat No.
CEI-0187
Description
Ruxolitinib (INCB018424) can inhibit JAK1, JAK2 and JAK3 with IC50 of 3 nM, 5 nM and 332 nM.
CAS No.
941678-49-5
Molecular Weight
306.37
Purity
>99%
Storage
2 years at -20centigrade Powder
Targets
Jak1, Jak2, Jak3
Molecular Formula
C17H18N6
Chemical Name
(3R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Solubility
DMSO 61 mg/mL Water
In vitro
Ruxolitinib (INCB-018424) is a potent, orally available, selective inhibitor of both JAK1 and JAK2 of the JAK-STAT signaling pathway, and INCB018424 (Ruxolitinib) inhibit Jak1, Jak2, and Jak3 with IC50 of 3 nM, 5 nM and 332 nM, respectively. Ruxolitinib (INCB-018424) is developed to target the constitutive activation of the JAK-STAT pathway in patients with myeloproliferative neoplasms (MPNs). Ruxolitinib (Jakafi; Incyte) is a small-molecule inhibitor of JAK1/2 that has proved to be effective at reducing splenomegaly and ameliorating symptoms in myeloproliferative neoplasms.
Download
Download Datasheet